CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia
This study aims to evaluate the safety and feasibility of CTA101 in treating patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia.
Acute Lymphoblastic Leukemia
BIOLOGICAL: CTA101
Dose-limiting toxicity（DLT）, Adverse events assessed according to NCI-CTCAE v5.0 criteria, Baseline up to 28 days after T cell infusion
MRD negative overall response rate (MRD- ORR), Assessment of MRD negative overall response rate (MRD- ORR) at 3 months of treatment, 3 months|Overall response rate (ORR), Assessment of ORR (ORR = CR + CRi ) at Month 6, 12, 18 and 24, Month 6, 12, 18 and 24|Event-free survival (EFS), Assessment of EFS at Month 6, 12, 18 and 24, Month 6, 12, 18 and 24|Overall survival (OS), Assessment of OS at Month 6, 12, 18 and 24, Month 6, 12, 18 and 24
This study is indicated for r/r CD19+ B-ALL, the selection of dose levels and the number of subjects are based on clinical trial of similar foreign product, whose primary objective was to explore the safety, main consideration was dose-related safety.